Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

ODM-201

ODM-201 administered orally daily

Trial Locations (23)

11215

Brooklyn Urology Research Group, Brooklyn

21327

Chesapeake Urology Research Associates, Baltimore

29572

Carolina Urologic Research Center, Myrtle Beach

34474

Urology Health Team PLLC, Ocala

44195

Cleveland Clinic, Cleveland

80211

The Urology Center of Colorado, Wheat Ridge

06360

Eastern CT Hematology and Oncology Associates, Norwich

08043

Delaware Valley urology, LLC, Voorhees Township

Unknown

Klinika onkologie a radioterapie LFUK a FN, Hradec Králové

Fakultni Nemonicnice Olomouc, Olomouc

Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo, Znojmo

East-Tallinn Central Hospital, Talinn

Helsinki University Central Hospital, Helsinki

Kuopio University Hospital, Kuopio

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Saint Louis Hospital, Paris

Institut Gustave Roussy, Villejuif

Queen Elizabeth Hospital, Birmingham

Velindre Cancer Centre, Cardiff

Christie Hospital, Manchester

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Endo Pharmaceuticals

INDUSTRY

lead

Orion Corporation, Orion Pharma

INDUSTRY